GCG and obesity due to melanocortin 4 receptor deficiency: Glucagon-like peptide-1 (GLP-1) analogues and other obesity interventions are gaining significant attention in the obesity epidemic [116, 117] and could perhaps also be an added area of exploration for ways to overcome the adverse effects of GC use that is vital to ALL therapy.